Full-spectrum Cannabis Extract in Refractory Epilepsy (Tuberous Sclerosis)

Introduction and clinical context

The study Full-spectrum Cannabis Extract in Refractory Epilepsy (Tuberous Sclerosis) (ClinicalTrials.gov · em andamento) is part of the scientific research on the use of cannabinoids in epilepsy.

Cannabidiol (CBD), the non-psychoactive compound of Cannabis sativa, is one of the best-documented applications of medical cannabis in controlling drug-resistant epileptic seizures. High-impact randomized clinical trials demonstrated a reduction in seizure frequency in severe childhood-onset syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome, underpinning regulatory approvals of purified CBD. Treatment requires prescription and neurological follow-up, with attention to dose titration and drug interactions.

Understanding what science shows about the use of cannabinoids in epilepsy helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This study is registered on ClinicalTrials.gov and is ongoing. Treats refractory epilepsy associated with tuberous sclerosis with full-spectrum cannabis extract. As it is ongoing, there are no final published results yet. Following ongoing studies is important to anticipate the next evidence on the topic.

Mechanism of action and safety

Cannabidiol exerts an anticonvulsant effect through multiple mechanisms, largely independent of the classic CB1/CB2 receptors, including the modulation of ion channels and neuronal excitability. Because it is not psychoactive, it has a profile distinct from THC. Regarding safety, drowsiness, diarrhea and a possible rise in liver enzymes stand out, which requires monitoring. The interaction with clobazam is clinically relevant and may require a dose adjustment. Treatment should be titrated gradually, under neurological supervision, with monitoring of adverse effects — redoubled care in children, the predominant population in these syndromes.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (ClinicalTrials.gov · em andamento). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does CBD treat epilepsy?

In specific refractory epilepsies, clinical trials showed a reduction in seizures; use is prescribed and monitored by a doctor.

Does CBD cause a psychoactive effect?

No. Cannabidiol is not psychoactive, unlike THC.